Author + information
- Robert Hamburger,
- Yan Gong,
- Jan Moreb,
- Carl Pepine,
- Alexandra Lucas and
- Anita Szady
Background: Reductions in global longitudinal strain (GLS) may be observed prior to the onset of systolic dysfunction in patients receiving trastuzumab and anthracycline agents and has been targeted as a method of early detection of cardiotoxicity. Data on cardiotoxicity in the setting of non-trastuzumab targeted agents are limited and there are no studies using strain imaging in this population.
Methods: We studied 13 patients on non-trastuzumab anticancer targeted therapies who subsequently developed reduced EF and compared GLS in these patients with 13 age and sex matched controls on similar agents with normal EF. GLS was obtained offline using TomTec software.
Results: Mean baseline EF was 58% in the cases, dropping to a mean of 30% after therapy. GLS pre and post treatment is shown in the figure. Patients with depressed EF had a lower baseline GLS vs patients with preserved EF (-15.5 ± 3.8 vs -20.4 ± 2.3, p= 0.002). As noted in the figure, 11 out of 13 patients who developed a cardiomyopathy had GLS below -20%, which is considered abnormal. There was a statistically significant drop in GLS in the cardiomyopathy group after treatment from -15.5 ± 3.8% to -10.9 ± 2.3% (p<0.001). In the control group the GLS remained unchanged from -20.4 ± 2.3% to -19.5 ± 3.0% (p = 0.18).
Conclusions: GLS declined significantly in patients who developed LV systolic dysfunction after non-trastuzumab anticancer targeted therapy compared to controls. Lower baseline GLS may predict development of systolic dysfunction in this population.
Poster Hall, Hall C
Saturday, March 18, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Novel Imaging and Therapies in Heart Failure
Abstract Category: 12. Heart Failure and Cardiomyopathies: Basic
Presentation Number: 1200-260
- 2017 American College of Cardiology Foundation